Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus.
Systemic sclerosis (SSc) is an uncommon connective tissue disease characterized by excessive collagen deposition within the skin and internal organs. Most patients with diffuse severe SSc are treated with immunosuppressive agents, but patients with advanced disease have very high 5-year mortality rates despite adequate therapy. We describe a patient with both diffuse cutaneous SSc and systemic lupus erythematosus who showed mixed chimerism 29 months after undergoing nonmyeloablative stem cell transplant. She experienced remission of both diseases.
Khorshid
Ola
O
Division of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Hosing
Chitra
C
Bibawi
Samer
S
Ueno
Naoto
N
Reveille
John
J
Mayes
Maureen D
MD
Champlin
Richard E
RE
D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D018570:Risk Assessment; D012595:Scleroderma, Systemic / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D012720:Severity of Illness Index; D033581:Stem Cell Transplantation / Q000379:methods*; D019172:Transplantation Conditioning; D016896:Treatment Outcome
D007166:Immunosuppressive Agents